Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.79 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.79 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673946 | 0.92 | SIRT1 (0.78) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL16266067 | 0.91 | SIRT1 (0.73) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL1875568 | 0.90 | SIRT1 (0.64) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL12990011 | 0.88 | SIRT1 (0.77) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL1275557 | 0.88 | SIRT1 (1.00) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL1874310 | 0.88 | SIRT1 (1.00) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL1870769 | 0.88 | SIRT1 (1.00) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL16266100 | 0.86 | SIRT1 (1.00) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL1873883 | 0.85 | SIRT1 (0.79) | SIRT1SIRT2SIRT3ALOX15LMNA | |
| SCHEMBL14881960 | 0.85 | MAPT (0.78) | SIRT1SIRT2SIRT3ALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | claimed |
| EP-1793817-A4 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS INC (US) | 2008-04-02 | — | — | EP | claimed |
| EP-1793817-A2 | METHODS OF TREATING A DISORDER | Elixir Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| EP-1677794-A2 | METHODS OF TREATING DISORDER | Elixir Pharmaceuticals, Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| US-20060074124-A1 | Methods of treating a disorder | IPSOL AG (LI) | 2006-04-06 | — | — | US | claimed |
| WO-2006031894-A2 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | claimed |
| US-20050209300-A1 | Methods of treating a disorder | IPSOL AG (LI) | 2005-09-22 | — | — | US | claimed |
| WO-2005026112-A2 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-20190314395-A1 | USE OF COMPOUNDS ACTIVATING SIRT-3 FOR MIMICKING EXERCISE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-10-17 | — | — | US | disclosed |
| US-20160263140-A1 | USE OF COMPOUNDS ACTIVATING SIRT-3 FOR MIMICKING EXERCISE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-09-15 | — | — | US | disclosed |
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| WO-2006031894-A2 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20050256181-A1 | Treating a viral disorder | ELIXIR PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050209300-A1 | Methods of treating a disorder | IPSOL AG (LI) | 2005-09-22 | — | — | US | disclosed |
| WO-2005072408-A2 | TREATING A VIRAL DISORDER | ELIXIR PHARMACEUTICALS, INC (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005026112-A2 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005026112-A2 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885SIRT2 3/4885SIRT3 2/4885 |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | SIRT1 1/4885SIRT2 2/4885SIRT3 5/4885 |
| US-20060074124-A1 | Methods of treating a disorder | CPT1B, CYP27A1, CLN6 | SIRT1 2717/4885SIRT2 3170/4885SIRT3 2488/4885 |
| US-20050209300-A1 | Methods of treating a disorder | CPT1B, CYP27A1, CLN6 | SIRT1 2717/4885SIRT2 3170/4885SIRT3 2488/4885 |
| US-20050256181-A1 | Treating a viral disorder | HAVCR2, EIF2AK2, RPL35 | SIRT1 1460/4885SIRT2 2707/4885SIRT3 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.